Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

CHRISTIAN STONE

Allopathic & Osteopathic Physicians Internal Medicine Gastroenterology

NPI
1750308284
CMS profile
170412
Location
LAS VEGAS, NV

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$235,578.01

288 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

By paying entity

PY2024 · entire year · sorted by reported total

Page 2 of 6; records 51–100 of 288 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

CHRISTIAN STONE

NPI 1750308284 · CMS profile ID 170412

Allopathic & Osteopathic Physicians / Internal Medicine / Gastroenterology

LAS VEGAS, NV

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 6; records 51–100 of 288 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1750308284?year=2024&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
CHRISTIAN STONE, NPI 1750308284, CMS profile ID 170412. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 6; records 51–100 of 288 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1750308284?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). CHRISTIAN STONE, NPI 1750308284, CMS profile ID 170412. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 6; records 51–100 of 288 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1750308284?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
CHRISTIAN STONE, NPI 1750308284, CMS profile ID 170412, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 6; records 51–100 of 288 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1750308284?year=2024&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

288 matching records · $235,578.01 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 288 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–100 of 288.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
ABBVIE INC. $124.7710/17/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1106169377 CMS
Takeda Pharmaceuticals U.S.A., Inc. $7,751.0010/17/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1137682721 CMS
Janssen Biotech, Inc. $112.4910/16/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078392963 CMS
Janssen Biotech, Inc. $432.4410/16/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078393368 CMS
Janssen Biotech, Inc. $625.5510/16/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078393836 CMS
ABBVIE INC. $2,875.0010/15/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1106169375 CMS
Janssen Biotech, Inc. $214.2910/15/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078392165 CMS
Janssen Biotech, Inc. $980.4010/15/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078395397 CMS
Janssen Biotech, Inc. $114.4010/15/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078395768 CMS
ABBVIE INC. $7.8210/09/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1106169373 CMS
Takeda Pharmaceuticals U.S.A., Inc. $5,729.0010/09/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1137682719 CMS
ABBVIE INC. $125.0010/08/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1106169371 CMS
ABBVIE INC. $15.7310/07/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1106169369 CMS
Lilly USA, LLC $18.0010/02/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1136100942 CMS
Lilly USA, LLC $20.1010/02/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1136107583 CMS
E.R. Squibb & Sons, L.L.C. $2,761.0009/25/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101705778 CMS
Lilly USA, LLC $2,200.0009/25/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1136098556 CMS
Lilly USA, LLC $2,500.0009/25/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1136119149 CMS
ABBVIE INC. $64.2509/24/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1106169367 CMS
ABBVIE INC. $2,875.0009/20/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1106169365 CMS
Lilly USA, LLC $121.8809/19/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1136094295 CMS
Lilly USA, LLC $690.8409/19/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1136100936 CMS
Lilly USA, LLC $1.0009/19/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1136107581 CMS
Lilly USA, LLC $353.2509/19/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1136116610 CMS
Lilly USA, LLC $64.2009/19/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1136119141 CMS
Takeda Pharmaceuticals U.S.A., Inc. $355.9509/18/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1137682711 CMS
Takeda Pharmaceuticals U.S.A., Inc. $467.2009/18/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1137682713 CMS
Takeda Pharmaceuticals U.S.A., Inc. $591.3509/18/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1137682715 CMS
Takeda Pharmaceuticals U.S.A., Inc. $121.8309/18/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1137682717 CMS
ABBVIE INC. $125.0009/17/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1106169363 CMS
Janssen Biotech, Inc. $20.2709/13/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078389607 CMS
Lilly USA, LLC $937.5009/13/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1136116618 CMS
E.R. Squibb & Sons, L.L.C. $123.9009/11/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101705774 CMS
Takeda Pharmaceuticals U.S.A., Inc. $1,083.3109/05/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1137682707 CMS
Takeda Pharmaceuticals U.S.A., Inc. $114.9609/05/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1137682709 CMS
Lilly USA, LLC $13.4008/28/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1136096903 CMS
Lilly USA, LLC $36.0008/28/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1136107579 CMS
Lilly USA, LLC $20.0008/28/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1136116616 CMS
ABBVIE INC. $13.5108/26/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1106169361 CMS
ABBVIE INC. $23.1208/25/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1106169359 CMS
ABBVIE INC. $30.4508/23/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1106169357 CMS
Takeda Pharmaceuticals U.S.A., Inc. $7,751.0008/23/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1137682701 CMS
Takeda Pharmaceuticals U.S.A., Inc. $18.0908/23/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1137682703 CMS
Takeda Pharmaceuticals U.S.A., Inc. $36.0008/23/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1137682705 CMS
ABBVIE INC. $125.2208/20/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1106169355 CMS
Janssen Biotech, Inc. $19.2608/20/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078394349 CMS
Lilly USA, LLC $2,500.0008/20/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1136094289 CMS
Lilly USA, LLC $2,200.0008/20/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1136116612 CMS
Lilly USA, LLC $2,500.0008/19/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1136096901 CMS
Regeneron Pharmaceuticals, Inc. $143.2508/19/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1114405451 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $172,216.69 247
PY2020 $66,175.07 135
PY2021 $95,654.79 155
PY2022 $220,590.34 270
PY2023 $177,686.12 262
PY2024 $235,578.01 288
PY2025 $167,465.92 212

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $293,184.74 54
PY2024 Principal investigator $281,884.79 86
PY2023 Principal investigator $352,472.05 75
PY2022 Principal investigator $406,228.43 59
PY2021 Recipient $11,197.58 2
PY2021 Principal investigator $450,854.90 89
PY2020 Principal investigator $386,773.20 104
PY2019 Recipient $38,397.78 3
PY2019 Principal investigator $371,546.48 70

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

54 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 GENZYME CORPORATION $4,979.00 12/22/2025 Non-covered Recipient Entity
Interspond LLC
A Randomized, Double-blind, Placebo Controlled, Dose-finding Study to Assess the Efficacy and Safety of SAR443122 in Adult Patients With Moderate to Severe Ulcerative Colitis No dispute reported 06/30/2026 1226148378
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $8,615.70 12/19/2025 Non-covered Recipient Entity
LAS VEGAS MEDICAL RESEARCH LLC
TAK-279-UC-2001 A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind Induction Study to Evaluate the Efficacy and Safety of Oral TAK-279 in Subjects With Moderately to Severely Active Ulcerative Colitis No dispute reported 06/30/2026 1223289960
Principal investigator 1 ABBVIE INC. $11,364.30 12/04/2025 Non-covered Recipient Entity
LAS VEGAS MEDICAL RESEARCH LLC
Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn s Disease (Target CD) No dispute reported 06/30/2026 1202527764
Principal investigator 1 ABBVIE INC. $36,264.20 12/04/2025 Non-covered Recipient Entity
LAS VEGAS MEDICAL RESEARCH LLC
Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn s Disease (Target CD) No dispute reported 06/30/2026 1202527768
Principal investigator 1 ABBVIE INC. $1,832.50 12/04/2025 Non-covered Recipient Entity
LAS VEGAS MEDICAL RESEARCH LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Upadacitinib (ABT-494) in Participants With Ulcerative Colitis (UC) No dispute reported 06/30/2026 1202527770
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $3,022.65 11/25/2025 Non-covered Recipient Entity
LAS VEGAS MEDICAL RESEARCH LLC
TAK-279-UC-2001 A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind Induction Study to Evaluate the Efficacy and Safety of Oral TAK-279 in Subjects With Moderately to Severely Active Ulcerative Colitis No dispute reported 06/30/2026 1223288743
Principal investigator 1 ABBVIE INC. $4,141.80 11/05/2025 Non-covered Recipient Entity
LAS VEGAS MEDICAL RESEARCH LLC
Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn s Disease (Target CD) No dispute reported 06/30/2026 1202522209
Principal investigator 1 ABBVIE INC. $3,491.00 11/04/2025 Non-covered Recipient Entity
LAS VEGAS MEDICAL RESEARCH LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Upadacitinib (ABT-494) in Participants With Ulcerative Colitis (UC) No dispute reported 06/30/2026 1202520515
Principal investigator 1 GENZYME CORPORATION $6,092.00 11/04/2025 Non-covered Recipient Entity
Interspond LLC
A Randomized, Double-blind, Placebo Controlled, Dose-finding Study to Assess the Efficacy and Safety of SAR443122 in Adult Patients With Moderate to Severe Ulcerative Colitis No dispute reported 06/30/2026 1226148323
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $1,354.50 11/04/2025 Non-covered Recipient Entity
Las Vegas Medical Research, LLC
A 44-Week Phase 2b Long-Term Extension, RandomizEd, Double-BLind, Study to Determine the Long-Term PharmacokInetics, Efficacy, Safety, and Tolerability of TEV-48574 in Adult PatiEnts With Moderate to Severe Ulcerative Colitis or Crohn's Disease Who Completed the Main Phase of the Dose-Ranging Study (RELIEVE UCCD LTE) No dispute reported 06/30/2026 1244040939
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,341.90 10/23/2025 Non-covered Recipient Entity
LAS VEGAS MEDICAL RESEARCH LLC
TAK-279-UC-2001 A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind Induction Study to Evaluate the Efficacy and Safety of Oral TAK-279 in Subjects With Moderately to Severely Active Ulcerative Colitis No dispute reported 06/30/2026 1223287437
Principal investigator 1 ABBVIE INC. $8,100.00 10/09/2025 Non-covered Recipient Entity
LAS VEGAS MEDICAL RESEARCH LLC
Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn s Disease (Target CD) No dispute reported 06/30/2026 1202515359
Principal investigator 1 ABBVIE INC. $6,391.75 10/09/2025 Non-covered Recipient Entity
LAS VEGAS MEDICAL RESEARCH LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Upadacitinib (ABT-494) in Participants With Ulcerative Colitis (UC) No dispute reported 06/30/2026 1202515361
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $4,727.70 10/03/2025 Non-covered Recipient Entity
LAS VEGAS MEDICAL RESEARCH LLC
A Double Blind, Randomized, Placebo Controlled, Parallel Group Study to Simultaneosly Qualify a Biomarker Algorithm for Prognosis of Risk of Developing Mild Cognitive Impairment due to Alzheimer's Disease (MCI due to AD) and to Test the Safety and Efficacy of Pioglitazone (AD-4833 SR 0.8 mg QD) to Delay the Onset of MCI due to AD in Cognitively Normal Subjects No dispute reported 06/30/2026 1223286251
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $303.75 10/03/2025 Non-covered Recipient Entity
LAS VEGAS MEDICAL RESEARCH LLC
A Double Blind, Randomized, Placebo Controlled, Parallel Group Study to Simultaneosly Qualify a Biomarker Algorithm for Prognosis of Risk of Developing Mild Cognitive Impairment due to Alzheimer's Disease (MCI due to AD) and to Test the Safety and Efficacy of Pioglitazone (AD-4833 SR 0.8 mg QD) to Delay the Onset of MCI due to AD in Cognitively Normal Subjects No dispute reported 06/30/2026 1223286253
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $100.00 10/03/2025 Non-covered Recipient Entity
LAS VEGAS MEDICAL RESEARCH LLC
A Double Blind, Randomized, Placebo Controlled, Parallel Group Study to Simultaneosly Qualify a Biomarker Algorithm for Prognosis of Risk of Developing Mild Cognitive Impairment due to Alzheimer's Disease (MCI due to AD) and to Test the Safety and Efficacy of Pioglitazone (AD-4833 SR 0.8 mg QD) to Delay the Onset of MCI due to AD in Cognitively Normal Subjects No dispute reported 06/30/2026 1223286255
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $6,499.99 10/03/2025 Non-covered Recipient Entity
LAS VEGAS MEDICAL RESEARCH LLC
A Double Blind, Randomized, Placebo Controlled, Parallel Group Study to Simultaneosly Qualify a Biomarker Algorithm for Prognosis of Risk of Developing Mild Cognitive Impairment due to Alzheimer's Disease (MCI due to AD) and to Test the Safety and Efficacy of Pioglitazone (AD-4833 SR 0.8 mg QD) to Delay the Onset of MCI due to AD in Cognitively Normal Subjects No dispute reported 06/30/2026 1223286279
Principal investigator 1 GENZYME CORPORATION $2,111.00 09/22/2025 Non-covered Recipient Entity
Interspond LLC
A Randomized, Double-blind, Placebo Controlled, Dose-finding Study to Assess the Efficacy and Safety of SAR443122 in Adult Patients With Moderate to Severe Ulcerative Colitis No dispute reported 06/30/2026 1226148241
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $6,500.25 09/18/2025 Non-covered Recipient Entity
LAS VEGAS MEDICAL RESEARCH LLC
A Double Blind, Randomized, Placebo Controlled, Parallel Group Study to Simultaneosly Qualify a Biomarker Algorithm for Prognosis of Risk of Developing Mild Cognitive Impairment due to Alzheimer's Disease (MCI due to AD) and to Test the Safety and Efficacy of Pioglitazone (AD-4833 SR 0.8 mg QD) to Delay the Onset of MCI due to AD in Cognitively Normal Subjects No dispute reported 06/30/2026 1223285638
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $3,022.65 09/18/2025 Non-covered Recipient Entity
LAS VEGAS MEDICAL RESEARCH LLC
A Double Blind, Randomized, Placebo Controlled, Parallel Group Study to Simultaneosly Qualify a Biomarker Algorithm for Prognosis of Risk of Developing Mild Cognitive Impairment due to Alzheimer's Disease (MCI due to AD) and to Test the Safety and Efficacy of Pioglitazone (AD-4833 SR 0.8 mg QD) to Delay the Onset of MCI due to AD in Cognitively Normal Subjects No dispute reported 06/30/2026 1223285640
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $750.00 09/04/2025 Non-covered Recipient Entity
LAS VEGAS MEDICAL RESEARCH LLC
A Double Blind, Randomized, Placebo Controlled, Parallel Group Study to Simultaneosly Qualify a Biomarker Algorithm for Prognosis of Risk of Developing Mild Cognitive Impairment due to Alzheimer's Disease (MCI due to AD) and to Test the Safety and Efficacy of Pioglitazone (AD-4833 SR 0.8 mg QD) to Delay the Onset of MCI due to AD in Cognitively Normal Subjects No dispute reported 06/30/2026 1223285105
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,500.00 09/04/2025 Non-covered Recipient Entity
LAS VEGAS MEDICAL RESEARCH LLC
A Double Blind, Randomized, Placebo Controlled, Parallel Group Study to Simultaneosly Qualify a Biomarker Algorithm for Prognosis of Risk of Developing Mild Cognitive Impairment due to Alzheimer's Disease (MCI due to AD) and to Test the Safety and Efficacy of Pioglitazone (AD-4833 SR 0.8 mg QD) to Delay the Onset of MCI due to AD in Cognitively Normal Subjects No dispute reported 06/30/2026 1223285107
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $9,331.20 08/21/2025 Non-covered Recipient Entity
LAS VEGAS MEDICAL RESEARCH LLC
TAK-279-UC-2001 A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind Induction Study to Evaluate the Efficacy and Safety of Oral TAK-279 in Subjects With Moderately to Severely Active Ulcerative Colitis No dispute reported 06/30/2026 1223284479
Principal investigator 1 GENZYME CORPORATION $11,282.00 08/18/2025 Non-covered Recipient Entity
Interspond LLC
A Randomized, Double-blind, Placebo Controlled, Dose-finding Study to Assess the Efficacy and Safety of SAR443122 in Adult Patients With Moderate to Severe Ulcerative Colitis No dispute reported 06/30/2026 1226148311
Principal investigator 1 ABBVIE INC. $3,915.00 08/06/2025 Non-covered Recipient Entity
LAS VEGAS MEDICAL RESEARCH LLC
Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn s Disease (Target CD) No dispute reported 06/30/2026 1202502636
Principal investigator 1 ABBVIE INC. $7,451.50 08/05/2025 Non-covered Recipient Entity
LAS VEGAS MEDICAL RESEARCH LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Upadacitinib (ABT-494) in Participants With Ulcerative Colitis (UC) No dispute reported 06/30/2026 1202501418
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,578.15 07/17/2025 Non-covered Recipient Entity
LAS VEGAS MEDICAL RESEARCH LLC
TAK-279-UC-2001 A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind Induction Study to Evaluate the Efficacy and Safety of Oral TAK-279 in Subjects With Moderately to Severely Active Ulcerative Colitis No dispute reported 06/30/2026 1223282782
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $721.80 07/10/2025 Non-covered Recipient Entity
Las Vegas Medical Research, LLC
A 44-Week Phase 2b Long-Term Extension, RandomizEd, Double-BLind, Study to Determine the Long-Term PharmacokInetics, Efficacy, Safety, and Tolerability of TEV-48574 in Adult PatiEnts With Moderate to Severe Ulcerative Colitis or Crohn's Disease Who Completed the Main Phase of the Dose-Ranging Study (RELIEVE UCCD LTE) No dispute reported 06/30/2026 1244040937
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $372.60 07/04/2025 Non-covered Recipient Entity
LAS VEGAS MEDICAL RESEARCH LLC
TAK-279-UC-2001 A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind Induction Study to Evaluate the Efficacy and Safety of Oral TAK-279 in Subjects With Moderately to Severely Active Ulcerative Colitis No dispute reported 06/30/2026 1223282236
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $100.00 07/04/2025 Non-covered Recipient Entity
LAS VEGAS MEDICAL RESEARCH LLC
TAK-279-UC-2001 A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind Induction Study to Evaluate the Efficacy and Safety of Oral TAK-279 in Subjects With Moderately to Severely Active Ulcerative Colitis No dispute reported 06/30/2026 1223282238
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $6,500.25 07/04/2025 Non-covered Recipient Entity
LAS VEGAS MEDICAL RESEARCH LLC
TAK-279-UC-2001 A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind Induction Study to Evaluate the Efficacy and Safety of Oral TAK-279 in Subjects With Moderately to Severely Active Ulcerative Colitis No dispute reported 06/30/2026 1223282240
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $335.00 06/24/2025 Non-covered Recipient Entity
LAS VEGAS MEDICAL RESEARCH LLC
TAK-279-UC-2001 A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind Induction Study to Evaluate the Efficacy and Safety of Oral TAK-279 in Subjects With Moderately to Severely Active Ulcerative Colitis No dispute reported 06/30/2026 1223281782
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $6,045.30 06/24/2025 Non-covered Recipient Entity
LAS VEGAS MEDICAL RESEARCH LLC
TAK-279-UC-2001 A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind Induction Study to Evaluate the Efficacy and Safety of Oral TAK-279 in Subjects With Moderately to Severely Active Ulcerative Colitis No dispute reported 06/30/2026 1223281784
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $4,347.00 06/12/2025 Non-covered Recipient Entity
LAS VEGAS MEDICAL RESEARCH LLC
TAK-279-UC-2001 A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind Induction Study to Evaluate the Efficacy and Safety of Oral TAK-279 in Subjects With Moderately to Severely Active Ulcerative Colitis No dispute reported 06/30/2026 1223281166
Principal investigator 1 ABBVIE INC. $14,770.00 06/11/2025 Non-covered Recipient Entity
LAS VEGAS MEDICAL RESEARCH LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Upadacitinib (ABT-494) in Participants With Ulcerative Colitis (UC) No dispute reported 06/30/2026 1202490901
Principal investigator 1 Amgen Inc. $6,000.00 06/04/2025 Non-covered Recipient Entity
INTERSPOND LLC
A Phase 2, Dose-finding, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Safety and Efficacy of Efavaleukin Alfa Induction Therapy in Subjects With Moderately to Severely Active Ulcerative Colitis No dispute reported 06/30/2026 1246642866
Principal investigator 1 ABBVIE INC. $1,491.00 06/03/2025 Non-covered Recipient Entity
LAS VEGAS MEDICAL RESEARCH LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Upadacitinib (ABT-494) in Participants With Ulcerative Colitis (UC) No dispute reported 06/30/2026 1202489443
Principal investigator 1 ABBVIE INC. $870.50 06/03/2025 Non-covered Recipient Entity
LAS VEGAS MEDICAL RESEARCH LLC
A Study of the Efficacy and Safety of Risankizumab in Participants With Crohn Disease No dispute reported 06/30/2026 1202489445
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $5,003.10 05/22/2025 Non-covered Recipient Entity
LAS VEGAS MEDICAL RESEARCH LLC
A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind Induction Study to Evaluate the Efficacy and Safety of Oral TAK-279 in Subjects With Moderately to Severely Active Ulcerative Colitis No dispute reported 06/30/2026 1223280122
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $3,612.60 05/22/2025 Non-covered Recipient Entity
LAS VEGAS MEDICAL RESEARCH LLC
A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind Induction Study to Evaluate the Efficacy and Safety of Oral TAK-279 in Subjects With Moderately to Severely Active Ulcerative Colitis No dispute reported 06/30/2026 1223280124
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $12,229.20 05/13/2025 Non-covered Recipient Entity
Las Vegas Medical Research, LLC
A 44-Week Phase 2b Long-Term Extension, RandomizEd, Double-BLind, Study to Determine the Long-Term PharmacokInetics, Efficacy, Safety, and Tolerability of TEV-48574 in Adult PatiEnts With Moderate to Severe Ulcerative Colitis or Crohn's Disease Who Completed the Main Phase of the Dose-Ranging Study (RELIEVE UCCD LTE) No dispute reported 06/30/2026 1244040935
Principal investigator 1 Janssen Research & Development, LLC $164.00 05/08/2025 Non-covered Recipient Entity
LAS VEGAS MEDICAL RESEARCH LLC
A Phase 2b3 Randomized Double blind Placebo controlled Parallel group Multi Center Protocol to Evaluate the Efficacy and Safety of Guselkumab in Participants with Moderately to Severely Active Ulcerative Colitis No dispute reported 06/30/2026 1175418607
Principal investigator 1 ABBVIE INC. $1,531.00 05/06/2025 Non-covered Recipient Entity
LAS VEGAS MEDICAL RESEARCH LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Upadacitinib (ABT-494) in Participants With Ulcerative Colitis (UC) No dispute reported 06/30/2026 1202481505
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $6,706.00 04/29/2025 Non-covered Recipient Entity
Las Vegas Medical Research, LLC
A 14 Week Phase 2b, Randomized, Double-Blind, Dose-Ranging Study to Determine the Pharmacokinetics, Efficacy, Safety and Tolerability of TEV-48574 in Adult Patients With Ulcerative Colitis or Crohn's Disease (RELIEVE UCCD) No dispute reported 06/30/2026 1244040925
Principal investigator 1 ABBVIE INC. $2,460.00 04/03/2025 Non-covered Recipient Entity
LAS VEGAS MEDICAL RESEARCH LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Upadacitinib (ABT-494) in Participants With Ulcerative Colitis (UC) No dispute reported 06/30/2026 1202474111
Principal investigator 1 Eli Lilly and Company $2,406.00 03/28/2025 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A PHASE 3, MULTICENTER, OPEN LABEL, LONG TERM EXTENSION STUDY TO EVALUATE THE LONG TERM EFFICACY AND SAFETY OF MIRIKIZUMAB IN PATIENTS WITH CROHNS DISEASE No dispute reported 06/30/2026 1187878269
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $3,483.00 03/13/2025 Non-covered Recipient Entity
Las Vegas Medical Research, LLC
A 44-Week Phase 2b Long-Term Extension, RandomizEd, Double-BLind, Study to Determine the Long-Term PharmacokInetics, Efficacy, Safety, and Tolerability of TEV-48574 in Adult PatiEnts With Moderate to Severe Ulcerative Colitis or Crohn's Disease Who Completed the Main Phase of the Dose-Ranging Study (RELIEVE UCCD LTE) No dispute reported 06/30/2026 1244040931
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $2,461.00 03/13/2025 Non-covered Recipient Entity
Las Vegas Medical Research, LLC
A 44-Week Phase 2b Long-Term Extension, RandomizEd, Double-BLind, Study to Determine the Long-Term PharmacokInetics, Efficacy, Safety, and Tolerability of TEV-48574 in Adult PatiEnts With Moderate to Severe Ulcerative Colitis or Crohn's Disease Who Completed the Main Phase of the Dose-Ranging Study (RELIEVE UCCD LTE) No dispute reported 06/30/2026 1244040933
Principal investigator 1 GENZYME CORPORATION $47,789.00 02/10/2025 Non-covered Recipient Entity
Interspond LLC
A Randomized, Double-blind, Placebo Controlled, Dose-finding Study to Assess the Efficacy and Safety of SAR443122 in Adult Patients With Moderate to Severe Ulcerative Colitis No dispute reported 06/30/2026 1226148020
Principal investigator 1 ABBVIE INC. $2,079.50 02/05/2025 Non-covered Recipient Entity
LAS VEGAS MEDICAL RESEARCH LLC
M14-533 - A Study to Evaluate the Long-Term Safety and Efficacy of Upadacitinib (ABT-494) in Participants With Ulcerative Colitis (UC) No dispute reported 06/30/2026 1202445153
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $3,022.65 01/17/2025 Non-covered Recipient Entity
LAS VEGAS MEDICAL RESEARCH LLC
A Double Blind, Randomized, Placebo Controlled, Parallel Group Study to Simultaneosly Qualify a Biomarker Algorithm for Prognosis of Risk of Developing Mild Cognitive Impairment due to Alzheimer's Disease (MCI due to AD) and to Test the Safety and Efficacy of Pioglitazone (AD-4833 SR 0.8 mg QD) to Delay the Onset of MCI due to AD in Cognitively Normal Subjects No dispute reported 06/30/2026 1223273967
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $303.75 01/17/2025 Non-covered Recipient Entity
LAS VEGAS MEDICAL RESEARCH LLC
A Double Blind, Randomized, Placebo Controlled, Parallel Group Study to Simultaneosly Qualify a Biomarker Algorithm for Prognosis of Risk of Developing Mild Cognitive Impairment due to Alzheimer's Disease (MCI due to AD) and to Test the Safety and Efficacy of Pioglitazone (AD-4833 SR 0.8 mg QD) to Delay the Onset of MCI due to AD in Cognitively Normal Subjects No dispute reported 06/30/2026 1223273969
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $167.50 01/17/2025 Non-covered Recipient Entity
LAS VEGAS MEDICAL RESEARCH LLC
A Double Blind, Randomized, Placebo Controlled, Parallel Group Study to Simultaneosly Qualify a Biomarker Algorithm for Prognosis of Risk of Developing Mild Cognitive Impairment due to Alzheimer's Disease (MCI due to AD) and to Test the Safety and Efficacy of Pioglitazone (AD-4833 SR 0.8 mg QD) to Delay the Onset of MCI due to AD in Cognitively Normal Subjects No dispute reported 06/30/2026 1223273971
Principal investigator 1 ABBVIE INC. $2,148.50 01/02/2025 Non-covered Recipient Entity
LAS VEGAS MEDICAL RESEARCH LLC
M14-533 - A Study to Evaluate the Long-Term Safety and Efficacy of Upadacitinib (ABT-494) in Participants With Ulcerative Colitis (UC) No dispute reported 06/30/2026 1202434973